KEY POINTS
- This narrative review synthesizes evidence on radiation-induced changes within the bone–tumor–marrow microenvironment, incorporating studies available through October 2026. The analysis covers external-beam radiotherapy (EBRT), beta-emitting radiopharmaceutical therapy, and alpha-emitting radiopharmaceutical therapy, with particular emphasis on bone-dominant metastatic castration-resistant prostate cancer. It integrates clinical and preclinical findings involving skeletal remodeling, hematopoiesis, vascular and immune responses, oxidative stress, and spatial molecular biology, but presents no new patient cohort or formal meta-analysis.
- Bone metastases develop within a biologically heterogeneous environment rather than an isolated tumor compartment. Osteoblasts, osteoclasts, hematopoietic stem and progenitor cells (HSPCs), mesenchymal stromal cells, endothelial cells, macrophages, and immune populations interact through signals including SCF, CXCL12, TGF-β, and inflammatory mediators. Metastatic prostate cancer cells can occupy normal hematopoietic stem-cell niches, potentially disrupting marrow regeneration and altering the local response to radiation. Consequently, tumor control and hematologic toxicity may arise from radiation effects on overlapping cellular compartments.
- External-beam radiotherapy provides spatially controlled irradiation but may expose substantial functional marrow. Established palliative regimens include 8 Gy in one fraction, 20 Gy in five fractions, and 30 Gy in ten fractions, with SBRT used in selected situations. Marrow exposure depends on target location, treatment volume, fractionation, and baseline hematopoietic reserve. Although pelvic chemoradiotherapy studies have demonstrated relationships between marrow dose-volume exposure and hematologic toxicity, these findings cannot be transferred directly to focal treatment of bone metastases, and no validated universal marrow dose constraint exists for this setting.
- Radiopharmaceuticals produce fundamentally different microscopic dose distributions. Lutetium-177–PSMA-617 delivers beta radiation according to PSMA expression, radioligand uptake, retention, and radioactive decay, with cross-fire irradiation of neighboring cells over prolonged exposure periods. In contrast, radium-223 is bone-seeking and concentrates near mineralized surfaces undergoing active remodeling, delivering short-range, high-LET alpha radiation. Investigational actinium-225–PSMA also delivers alpha particles but targets PSMA-expressing cells rather than mineralized bone. These differences prevent straightforward comparison of biological effects using organ- or lesion-averaged absorbed dose alone.
- Radiation-induced skeletal injury involves interactions between bone-forming and bone-resorbing cells. Experimental radium-223 studies demonstrated trabecular bone loss, impaired osteoblast activity, altered osteoclast dynamics, and subsequent marrow adipogenesis, while zoledronic acid prevented trabecular bone loss in the investigated model. Clinically, the ERA 223 and PEACE-3 experiences highlight fracture risk during combination systemic therapy and the importance of bone-protecting agents. However, the observed clinical fracture differences cannot be attributed solely to direct irradiation of skeletal cells, given the contributions of background disease, systemic treatment, and patient selection.
- Hematopoietic injury involves both direct progenitor-cell damage and persistent alteration of supporting marrow niches. Radiation can induce DNA damage, ROS accumulation, mitochondrial dysfunction, senescence-associated changes, and impaired stromal support, potentially limiting hematopoietic recovery even when some stem cells survive. In patients receiving 177Lu-PSMA, greater PET-defined bone tumor volume has been associated with severe hematologic toxicity. A small clinical radium-223 study also associated urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) with subsequent marrow suppression, although its prospective predictive value remains unvalidated.
- The review proposes integrating spatial dosimetry with molecular characterization of marrow responses. Transcriptomics, proteomics, metabolomics, lipidomics, and single-cell or spatial profiling could help distinguish radiation-associated tumor suppression from stromal remodeling, metabolic adaptation, immune dysfunction, and hematopoietic injury. The proposed future planning framework incorporates three dimensions: tumor dose and coverage, functional marrow dose and reserve, and local microenvironmental state. However, no prospective trial has validated such an integrated decision algorithm, and molecular findings have not yet produced routine clinical thresholds for selecting or sequencing EBRT and radiopharmaceutical therapy.
CLINICAL TAKEAWAY
Radiotherapy for bone metastases affects malignant cells alongside skeletal, vascular, immune, and hematopoietic compartments, with important differences between externally delivered radiation and systemic radiopharmaceuticals. These biological distinctions support consideration of functional marrow reserve and prior radiation exposure during treatment selection, but spatial molecular profiling and proposed microenvironment-based planning strategies remain investigational.